slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 34,291-34,320
Pages 1,379
Rows per page 30
Component
34,291-34,320 of 41,369
04
The slide uses a circular hub-and-spoke diagram centered on 'Patients' to connect three core pillars: Need, Speed, and Power.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Logic Chain1 hit
06
The slide highlights the competitive advantage of scale and recontactability, supported by a callout on consent rates and a metric on drug success probability.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Logic Chain1 hit
08
The slide uses a '2x-3x' metric to justify the value of genetic support in drug discovery, citing Nelson et al. (2015) and King et al. (2019).23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Logic Chain1 hit
23
Includes survival curves, immunohistochemistry images, genetic association data, and clinical trial data for atopic dermatitis.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
32
The slide uses a combination of a data table, a biological mechanism diagram, and a summary of clinical validation to support the therapeutic thesis.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses a combination of a biological process diagram and a line chart showing tumor cell reduction over time.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a structured layout to present clinical outcomes alongside a study overview box.Alkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · EvidenceLoop · Voice Of Customer1 hit
27
Alkermes | Investor Conference Presentation Deck | 29 slidesAlkermes | Investor Conference Presentation Deck | 29 slides · Alkermes
Conference presentation Investor relations Beat · Resolution1 hit
18
Data presented at AASLD 2023. Shows ELISpot results for T cell responses and HBsAg levels.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
21
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
Includes both in vitro (IFN-y fold increase) and in vivo (MC38 tumor model) efficacy data.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide highlights the progression of delivery technology enabled by the ENHANZE license.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
23
The diagram is a variation of a flywheel or infinity loop representing the integration of clinical development and disease insight.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
16
The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
19
The slide highlights both internal R&D focus areas and external acquisitions (Cellectis, Quell, Gracell) to support long-term growth.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
08
The slide outlines a 12-week open-label study with a specific focus on treatment-resistant depression (TRD).ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
The slide uses a process flow diagram to show the progression of the trial parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a line chart to show the change in MADRS scores over 12 weeks for three different dosages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes trial objectives and timeline markers for both parts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
Includes a map of the world as a visual anchor for global disease burden.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a grouped bar chart to visualize T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage cohorts.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses EEG power spectral density analysis to demonstrate target engagement and potential for a superior safety profile (less sedation) compared to standard benzodiazepines.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
03
The slide uses a three-column layout to categorize revenue streams: Drug Discovery (yellow), Development Pipeline (orange), and Knowledge Exploration Tools (teal).BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a value-chain style flow from left to right, emphasizing the integration of diverse data types into a central knowledge graph.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
40
The slide uses a visual comparison of men's vs women's product categories and gender mix percentages to identify a gap in the women's accessories segment.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
74
The slide uses a minimalist aesthetic with a large portrait and a single sentence of text.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
105
The slide uses a visual hierarchy connecting product icons to strategic pillars.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
115
The slide uses a pyramid shape filled with a landscape image to represent the journey.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit